New research by health economists at the University of York has raised concerns over any move to broaden the range of costs and economic benefits considered in the analysis of new NHS treatments.
Patient: "Forty-six thousand Canadians are diagnosed with kidney cancer a year and 16,000 will die. I know kidney cancer isn't as high profile as prostate or breast cancer, but we need access to life improving drugs."
Congress' health-care reform efforts to date have not given people confidence that the final outcome will meet goals such as greater access, affordability and quality, said Marie Gross, a Bedford health-care consultant. Subsequent reform efforts should pay greater attention to enhancing transparency and emphasizing patients' personal responsibility for their health.
Patient advocate Katherine Phillion's notes from our fall kidney cancer meeting, in Chicago.
Obesity increases the risk of developing a common and virulent form of kidney cancer, a new study finds.
Canadian patients there is no accurate count seek treatment in the United States and pay out of pocket.
Antigenics Inc. has spent between $400 million and $500 million to conduct two Phase 3 trials on its potential cancer vaccine. But the Lexington-based company never plans to send it to the U.S. Food and Drug Administration for approval.
Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study
We performed fluorescent in situ hybridization (FISH) to investigate the numeric change of chromosomes 7, 17, and Y and loss of chromosome 3p in "papillary renal cell carcinomas (RCC) with extensive clear cell changes (CCC)." Consecutive cases of RCC over a 12-year period were reviewed to identify "papillary RCC with extensive CCC." Immunostaining for cytokeratin 7 and alpha-methylacyl-CoA racemase (AMACR) and FISH for chromosomes 7, 17, Y, and 3p were applied.
|NeonCRM by Neon One|